Evidence map›Paper›PMID 24600277›Full record

ReviewAdolescent health, medicine and therapeutics2011

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients.

Joanna Dobroszycki, Jacobo Abadi, Andrew A Wiznia, Michael G Rosenberg

Abstract readReview
In one paragraph

Review in Adolescent health, medicine and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joanna DobroszyckiDepartment of Pediatrics, Division of Infectious Diseases, Jacobi Medical Center, Bronx, NY, USA.
Jacobo AbadiDepartment of Pediatrics, Division of Infectious Diseases, Jacobi Medical Center, Bronx, NY, USA.
Andrew A WizniaDepartment of Pediatrics, Division of Infectious Diseases, Jacobi Medical Center, Bronx, NY, USA.
Michael G RosenbergDepartment of Pediatrics, Division of Infectious Diseases, Jacobi Medical Center, Bronx, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of protease inhibitors (PI) containing antiretroviral regimens in the treatment of HIV infection in infants, children, and adolescents has dramatically decreased morbidity and mortality. Darunavir, the latest PI to be FDA approved for pediatric patients older than 6 years and currently the preferred PI for use in adult patients, was added as an alternative PI for use in children based on a combination of data from both adult and pediatric trials. This review of darunavir in the treatment of HIV-infected children and adolescents looks at the major published clinical trials findings, pharmacokinetic and resistance studies, and preliminary data on use in younger children.

Indexed as

darunavirHIVprotease inhibitor

Identifiers

PMID24600277
PMCPMC3926773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.